Detailed Narrative
Q3 FY25 Financial Performance Overview
Glenmark Pharmaceuticals reported a consolidated revenue from operations of INR 33,876 million in Q3 FY25, marking a 35.1% YoY growth. For the first nine months of FY25, consolidated revenue reached INR 1,00,655 million, up 15% YoY. R&D expenditure for Q3 stood at INR 225 crores, representing 6.6% of sales, with an additional USD 13.8 million invested in IGI. The company also reported a forex gain of INR 23 crores and a net debt of INR 109 crores as of December 2024.
India Business & New Launches
The India formulation business recorded a significant 300% YoY growth in Q3 FY25, reaching INR 10,637 million, contributing 31.4% to overall revenue. Glenmark outperformed the Indian pharmaceutical market, with secondary sales growing 9.6% in Q3 FY25 (vs. market growth of 7.2%). Key therapeutic areas like dermatology and cardiac performed well. The company launched LIRAFIT (biosimilar Liraglutide) and JABRYUS (Abrocitinib) and plans to launch two oncology products (Tislelizumab and Zanubrutinib) in partnership with BeiGene within the next 3-4 months.
North America Business & Monroe Plant
The North America business saw a modest 1.4% YoY growth, with revenue at INR 7,813 million in Q3 FY25. The segment faced challenges due to a lack of meaningful launches but anticipates an uptick from FY26, driven by respiratory and injectable segments. Glenmark expects to launch respiratory ANDAs from H1 FY26, including Fluticasone 44 MDI, which is projected to have an exclusive position. The Monroe plant, critical for 25-30% of US revenues, is awaiting an FDA inspection, though the company continues to file products from it.
Europe & ROW Performance
Europe operations delivered a strong 14.8% YoY growth, with revenue reaching INR 7,297 million in Q3 FY25, contributing 21.5% to total revenues. The branded business, particularly RYALTRIS and Salmex, sustained growth. The ROW region grew 3% YoY to INR 7,491 million, but growth was impacted by adverse currency movements. RYALTRIS continued its strong performance in Russia, Latin America, and Australia, with FY25 sales projected to reach $80 million and peak sales of $200-300 million over time.
Ichnos Glenmark Innovation (IGI) & Pipeline
IGI's ISB 2001, a trispecific antibody for multiple myeloma, showed promising Phase 1 trial data with an 83% overall response rate. Glenmark has initiated partnering discussions post the ASH conference and aims to conclude a deal in calendar year 2025, expecting FY26 to be the last year Glenmark will need to fund IGI directly. The long-term goal for IGI is an IPO in the US. The company also has other innovative oncology molecules and out-licensed autoimmune assets.
Future Growth Drivers & Margin Outlook
Management highlighted several key growth drivers, including the upcoming US respiratory launches (Fluticasone MDI, nasal sprays) with a potential market of $600-700 million by FY27, and three 180-day exclusivities in FY27-28 representing an $800 million market. The company expects a 1-1.5% year-on-year improvement in EBITDA margins, adjusted for currency impacts, and aims to meet its full-year top-line and EBITDA guidance.